The results presented in this systematic review and meta-analysis contribute to refining the knowledge about the relevance of IL-33 in individuals with obesity and T2D, guiding future research and enriching the broader discourse on therapeutic targets for metabolic disorders. Here, IL33 is linked to obesity due to melanocortin 4 receptor deficiency.